Isoform-selective phosphoinositide 3-kinase inhibitors induce apoptosis in chronic lymphocytic leukaemia cells: Correspondence

British Journal of Haematology

Volumn 150, Issue 1, 2010, Pages 108-110

  De Frias, Mercè ^a   Iglesias Serret, Daniel ^a   Cosialls, Ana M ^a   González Gironès, Diana M ^a   Pérez Perarnau, Alba ^a   Rubio Patiño, Camila ^a   Rückle, Thomas ^b   Camps, Montserrat ^b   De Sevilla, Alberto Fernández ^c   De La Banda, Esmeralda ^d   Pons, Gabriel ^a   Gil, Joan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MERCK SERONO S A   (Switzerland)

^c L'Hospitalet de Llobregat   (Switzerland)

^d HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Apoptosis; Chronic lymphocytic leukaemia; Phosphoinositide 3 kinase

Indexed keywords

2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 5 [5 (4 FLUORO 2 HYDROXYPHENYL)FURFURYLIDENE] 2,4 THIAZOLIDINEDIONE; AS 702630; G PROTEIN COUPLED RECEPTOR; MSC 1822169B; MSC 1829899A; MSC 1831419A; MSC 1902994A; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN P110; TGX 115; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; WORTMANNIN;

APOPTOSIS; B LYMPHOCYTE; CATALYSIS; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CYTOTOXICITY; HUMAN; IC 50; IN VITRO STUDY; LETTER; LEUKEMIA CELL; LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN LOCALIZATION; T LYMPHOCYTE;

EID: 77953504223     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2010.08151.x     Document Type: Letter

References (10)

1. Barragan, M., Bellosillo, B., Campas, C., Colomer, D., Pons, G. Gil, J. (2002) Involvement of protein kinase C and phosphatidylinositol 3-kinase pathways in the survival of B-cell chronic lymphocytic leukemia cells. Blood, 99, 2969 2976.
2. Bilancio, A., Okkenhaug, K., Camps, M., Emery, J.L., Ruckle, T., Rommel, C. Vanhaesebroeck, B. (2006) Key role of the p110delta isoform of PI3K in B-cell antigen and IL-4 receptor signaling: comparative analysis of genetic and pharmacologic interference with p110delta function in B cells. Blood, 107, 642 650.
3. Draghetti, C., Salvat, C., Zanoguera, F., Curchod, M.L., Vignaud, C., Peixoto, H., Di Cara, A., Fischer, D., Dhanabal, M., Andreas, G., Abderrahim, H., Rommel, C. Camps, M. (2009) Functional whole-genome analysis identifies polo-like kinase 2 and poliovirus receptor as essential for neuronal differentiation upstream of the negative regulator alphaB-crystallin. The Journal of Biological Chemistry, 284, 32053 32065.
4. Engelman, J.A., Luo, J. Cantley, L.C. (2006) The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nature Reviews. Genetics, 7, 606 619.
5. Hamblin, A.D. Hamblin, T.J. (2008) The immunodeficiency of chronic lymphocytic leukaemia. British Medical Bulletin, 87, 49 62.
6. Jackson, S.P., Schoenwaelder, S.M., Goncalves, I., Nesbitt, W.S., Yap, C.L., Wright, C.E., Kenche, V., Anderson, K.E., Dopheide, S.M., Yuan, Y., Sturgeon, S.A., Prabaharan, H., Thompson, P.E., Smith, G.D., Shepherd, P.R., Daniele, N., Kulkarni, S., Abbott, B., Saylik, D., Jones, C., Lu, L., Giuliano, S., Hughan, S.C., Angus, J.A., Robertson, A.D. Salem, H.H. (2005) PI 3-kinase p110beta: a new target for antithrombotic therapy. Nature Medicine, 11, 507 514.
7. Manning, B.D. Cantley, L.C. (2007) AKT/PKB signaling: navigating downstream. Cell, 129, 1261 1274.
8. Marone, R., Cmiljanovic, V., Giese, B. Wymann, M.P. (2008) Targeting phosphoinositide 3-kinase: moving towards therapy. Biochimica Et Biophysica Acta, 1784, 159 185.
9. Niedermeier, M., Hennessy, B.T., Knight, Z.A., Henneberg, M., Hu, J., Kurtova, A.V., Wierda, W.G., Keating, M.J., Shokat, K.M. Burger, J.A. (2009) Isoform-selective phosphoinositide 3′-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood, 113, 5549 5557.
10. Pleyer, L., Egle, A., Hartmann, T.N. Greil, R. (2009) Molecular and cellular mechanisms of CLL: novel therapeutic approaches. Nature Reviews. Clinical Oncology, 6, 405 418.